Literature DB >> 3925638

Polycystic ovarian disease.

E Schriock, M C Martin, R B Jaffe.   

Abstract

Polycystic ovarian disease represents a poorly defined spectrum of clinical disorders having oligo-ovulation or anovulation as a common feature. There is no single, universally accepted biochemical or clinical definition. Clinical findings usually include anovulation resulting in irregular uterine bleeding and infertility, androgen excess resulting in hirsutism and acne, and obesity. The patho-physiology involves altered functions of the hypothalamus, pituitary, ovary and adrenal glands, resulting in failure of folliculogenesis to regularly proceed to ovulation. The cause of the initiating event in this disease process remains enigmatic. Therapy for the various abnormalities in polycystic ovarian disease is tailored to a patient's needs and may include preventing endometrial hyperplasia, controlling irregular uterine bleeding, controlling hirsutism and inducing ovulation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3925638      PMCID: PMC1306076     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  12 in total

1.  Adrenal function in normal women and women with the polycystic ovary syndrome.

Authors:  G C Lachelin; M Barnett; B R Hopper; G Brink; S S Yen
Journal:  J Clin Endocrinol Metab       Date:  1979-12       Impact factor: 5.958

Review 2.  The polycystic ovary syndrome.

Authors:  S S Yen
Journal:  Clin Endocrinol (Oxf)       Date:  1980-02       Impact factor: 3.478

Review 3.  Polycystic ovarian disease.

Authors:  J W Goldzieher
Journal:  Fertil Steril       Date:  1981-04       Impact factor: 7.329

4.  Functional studies of aromatase activity in human granulosa cells from normal and polycystic ovaries.

Authors:  G F Erickson; A J Hsueh; M E Quigley; R W Rebar; S S Yen
Journal:  J Clin Endocrinol Metab       Date:  1979-10       Impact factor: 5.958

5.  Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome.

Authors:  R Rebar; H L Judd; S S Yen; J Rakoff; G Vandenberg; F Naftolin
Journal:  J Clin Invest       Date:  1976-05       Impact factor: 14.808

6.  Abnormal luteinizing hormone response patterns to synthetic gonadotrophin releasing hormone in patients with polycystic ovarian syndrome.

Authors:  M Katz; P J Carr
Journal:  J Endocrinol       Date:  1976-08       Impact factor: 4.286

7.  Prolactin release in polycystic ovary.

Authors:  P Falaschi; E del Pozo; A Rocco; V Toscano; E Petrangeli; P Pompei; G Frajese
Journal:  Obstet Gynecol       Date:  1980-05       Impact factor: 7.661

8.  The use of human gonadotropins for the induction of ovulation in women with polycystic ovarian disease.

Authors:  C F Wang; C Gemzell
Journal:  Fertil Steril       Date:  1980-05       Impact factor: 7.329

9.  A novel use of spironolactone: treatment of hirsutism.

Authors:  G Shapiro; S Evron
Journal:  J Clin Endocrinol Metab       Date:  1980-09       Impact factor: 5.958

10.  Levels of inhibin-F activity and steroids in human follicular fluid from normal women and women with polycystic ovarian disease.

Authors:  K Tanabe; P Gagliano; C P Channing; Y Nakamura; Y Yoshimura; R Iizuka; A Fortuny; J Sulewski; N Rezai
Journal:  J Clin Endocrinol Metab       Date:  1983-07       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.